ClinicalTrials.gg
CompletedNCT06655194Updated Apr 15, 2025

A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants

A Phase 1 interventional study of Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477) and Acetylsalicylic Acid (BAYE004465, UI1615160) in Bioequivalence, Healthy Volunteers and Platelet Aggregation Inhibition, sponsored by Bayer. Completed at 1 site in Mexico. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

In this study, researchers want to learn if 2 different forms of acetylsalicylic acid (ASA) chewable tablets will have the same effect in the body. For this, they compared the blood levels of a new form of ASA chewable tablet, which is manufactured at a different site, with an approved ASA chewable tablet, on an empty stomach in healthy participants. This is done as part of the regulatory requirement for the marketing approval of the new ASA chewable tablet.

The study treatment, ASA, is an antiplatelet drug. It works by making the blood thinner and stopping the blood from clotting.

In this study, participants will be healthy and will not benefit from taking ASA chewable tablets. However, the study will provide information on how the new ASA chewable tablet, which is manufactured at a different site, has an effect on the body.

The main purpose of this study is to compare blood levels of the new ASA chewable tablet with the approved ASA chewable tablet when taken as a single dose on an empty stomach.

For this, the researchers will analyze:

  • Area under the curve (AUC): a measure of the total amount of ASA in participants' blood over time
  • Maximum observed concentration (Cmax): the highest amount of ASA in participants' blood after a single dose without food

This study will have 3 treatment periods of 4 days each. In each period, participants will take either the new or approved ASA chewable tablet on an empty stomach according to the order assigned to them. The 2 treatment sequences in this study are:

New chewable tablet, approved chewable tablet, new chewable tablet

Approved chewable tablet, new chewable tablet, approved chewable tablet

Each participant will be in the study for around 7 weeks, which includes:

  • a visit within 21 days of the first period to confirm if the participant can take part in the study
  • hospital stay of around 2 days in each period, during which, participants will take their assigned treatment, and have blood tests to check for drug levels
  • a gap of 1 week after taking the treatment in each period

During the study, the doctors and their study team will:

  • measure the level of the study treatment by taking blood samples
  • check participants' health by performing urine tests, checking vital signs and checking heart health using an electrocardiogram (ECG)
  • ask the participants questions about how they are feeling and what adverse events they are having

An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

As this study is conducted in healthy participants who will not benefit from the treatment, access to the treatment after the study is not planned.

02

Conditions studied

  • Bioequivalence
  • Healthy Volunteers
  • Platelet Aggregation Inhibition
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Healthy, ambulatory male and female subjects between 18 to 55 years of age the health status will be assured by a complete physical examination, medical history, (ECG), vital sign measurement, and clinical laboratory testing.
  • Subjects with a body weight of at least 50 kg and a (BMI) between 18.0 to 27 kg/m2 according to Quetelet index.
  • Subjects who have signed the authorization for clinical examinations (F-21 C) as well as the informed consent (F-07 C) before carrying out any procedure pertaining to the study.
  • Subjects with legal capacity.
  • Subjects understanding the nature, scope and risk/benefit of the trial and willing to adhere to the study procedures.
  • Subjects presenting the following ranges of physiologic parameters at the selection visit: systolic blood pressure (seated) for 90 to 139 mm/Hg, diastolic blood pressure from 60 to 89 mg/Hg, heart rate between 50 and 100 beats per minute and respiratory rate between 14 and 20 breaths per minute.
  • ECG, Hematic Biometry, Urinalysis, Biochemical Profile in normal reference ranges.
  • The participants (women) agree to take the necessary measures to avoid conception during the entire study and up to two weeks after its end.
  • Female subjects must present a negative result for pregnancy.
  • Subjects have to present a negative result for the antibodies of and .
  • Subjects have to present a negative result with respect to Anti- (HIV) 1 and Anti-HIV 2 antibodies.
  • Subjects have to present a negative result with respect to venereal disease research lab (RPR) test.
  • Subjects have to present a negative result with respect to drug abuse (amphetamines, cocaine, cannabis, benzodiazepines and barbiturates) performed during the selection process/beginning of each study period.
  • Subjects have to present a negative saliva alcohol test result at the beginning of each study period.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any finding of physical examination (including blood pressure, heart and respiratory rate, , and body temperature [forehead]) outside of normal ranges and of clinical relevance.
  • History of asthma, urticaria or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Severe heart failure.
  • Subjects with a history of chronic or recurrent cardiovascular, renal, hepatic, muscle, metabolic, immunological, gastrointestinal (especially history of bleeding, chronic gastritis or peptic ulcers) including constipation, neurological problems (especially history of epileptic seizures), endocrine, hematopoietic or any type of anemia, asthma, mental illness or other organic abnormalities.
  • Subjects with a muscle injury within a range of 21 days prior to the start of the study.
  • Subjects with a hereditary problem of galactose intolerance, lactase deficiency, or glucose-galactose mal-absorption.
  • Subjects who need any type of medication besides the study drug (exception: paracetamol up to 1 g/day).
  • Subjects that have been exposed to drugs known as inductors or liver enzyme inhibitors or who have taken drugs which are capable of altering the urinary pH, like antacids with sodium bicarbonate, potassium citrate, diuretics, or any potentially toxic drugs within the 30 days prior to the beginning of the study.
  • Subjects who have received any prescribed or over-the-counter (OTC) drug product, including vitamins and herbal remedies 30 days (or 7 half-lives) prior to the beginning of the study.
  • Subjects who have been hospitalized for any disorder within seven months prior to the beginning of the study.
  • Subjects who received products within 90 days prior to the study.
  • Subjects with a known to any of the ingredients of the test or reference formulation.
  • Subjects presenting a food allergy.
  • Subjects who have consumed charcoal grilled nourishment 48 hours prior to the beginning of both study periods.
  • Subjects consuming xanthine- and quinine-containing food and beverages and certain fruit juices such as grapefruit juice within 48 hours before investigational medicinal product (IMP) administration.
  • Subjects having consumed alcohol within 48 hours before screening and within 12 hours before IMP administration (on Day -1 verified by saliva alcohol test).
  • Smokers or currently consuming any type of tobacco product(s) including any smoking cessation nicotine-containing product within the previous three months (e.g., nicotine patch, nicotine gum).
  • Subjects consuming xanthine excessively (more than 5 cups of coffee or equivalent beverages like energy drinks per day).
  • Subjects who have donated or lost 450 mL or more blood within the 90 days prior to the beginning of the study.
  • Subjects with a record of alcoholism and drug abuse, psycho-active substances or chronic medication during the previous 2 years.
  • Subjects who require special diet for any reason, for example vegetarian diet.
  • Subjects with any incapacity to understand the nature, purpose and possible consequences of the study.
  • Subjects unwilling to follow study requirements and procedures.
  • Subjects presenting a positive test for surface antigen test, anti , virus (Anti-HCV), or -1/2 antibodies and HIV-1 p24-antigen.
  • Subjects presenting a positive drug screen test or any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine and cannabis.
  • Subjects with any active disease, acute or chronic.
  • Subjects with febrile or infectious illness within 1 week before screening.
  • Subjects with any other disease or condition which could influence the metabolism of the drug (e.g., endocrine diseases).
  • Subjects with any gastrointestinal complaints within 1 week before screening (gastrointestinal disorders including irritable bowel and gastrointestinal ulcer or bleeding).
  • Subjects with a medical disorder, condition or history of such disorder or condition that could impair the subject's ability to participate or complete this trial in the opinion of the investigator.
  • Subjects practicing sports excessively within 5 days before start of the treatment phase.
  • Subjects with a complete body fungal infection.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Comparator-test-comparator

    Participants will be randomly assigned to the treatment sequence "comparator-test-comparator" according to a computer-generated randomization list.

    Drug: Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477) · Drug: Acetylsalicylic Acid (BAYE004465, UI1615160)

  • Experimental
    Test-comparator-test

    Participants will be randomly assigned to the treatment sequence "test-comparator-test" according to a computer-generated randomization list.

    Drug: Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477) · Drug: Acetylsalicylic Acid (BAYE004465, UI1615160)

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-tlast) of ASA

    AUC(0-tlast): AUC from time 0 to the last data point \> lower limit of quantitation (LLOQ)

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

  2. Cmax of ASA

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

Secondary outcomes

  1. AUC of ASA and salicylic acid

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

  2. Ke of ASA and salicylic acid

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

  3. t1/2 of ASA and salicylic acid

    t1/2: half-life associated with the terminal slope

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

  4. tmax of ASA and salicylic acid

    tmax: time to reach Cmax (in case of two identical Cmax values, the first tmax will be used)

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

  5. Cmax of salicylic acid

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

  6. AUC(0-tlast) of salicylic acid

    Time frame: Baseline (pre-dose) and at 0.083, 0.166, 0.250, 0.333, 0.416, 0.500, 0.583, 0.666, 0.750, 0.833, 0.916, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 4.50, 5.00, 7.00, 9.00, 12.00 and 24.00 hours post dose in each treatment period

07

Study locations

1 site
  • IPharma, S.A. de C.V.
    Monterrey, Nuevo Leon 64460, Mexico
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 23, 2024
StartActual
Feb 26, 2025
Primary completionActual
Apr 6, 2025
CompletionActual
Apr 6, 2025
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655194
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Feb 26, 2025
Primary completion
Apr 6, 2025
Completion
Apr 6, 2025
Last update
Apr 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion